negative effects of semaglutide Comparative safety and side and tirzepatide: Implications for clinical decision-making in obesity management Top 5 Common Semaglutide Side

What is GLP-1 Medication

The biochemistry is identical

Considering these factors, PYY analogues will likely be employed in future in combination with GLP-1 or other gut hormones, to enhance weight loss

Semaglutide vs Tirzepatide: The Core Differences Comparison point Semaglutide Tirzepatide Hormone pathway GLP-1 receptor agonist Dual GIP and GLP-1 receptor agonist Weight-management brand Wegovy Zepbound Diabetes brand with the same active ingredient Ozempic Mounjaro Current weight-management forms Injection and tablet Injection Direct 72-week obesity trial 13.7% mean weight reduction 20.2% mean weight reduction Notable FDA-labeled consideration Major cardiovascular event risk reduction in certain adults with established cardiovascular disease and overweight or obesity Moderate to severe obstructive sleep apnea in adults with obesity Main tolerability concern Gastrointestinal symptoms Gastrointestinal symptoms SURMOUNT-5 was a randomized phase 3b trial of adults with obesity without diabetes treated with maximum tolerated doses for 72 weeks